42 results
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
16 Jul 20
Results of Operations and Financial Condition
9:17am
with 27G proprietary injector Resides in the iridocorneal angle Fully biodegradable Preservative-free ONGOING PHASE 1 CLINICAL TRIAL Implant has … -free Designed to deliver effective therapy up to 12 weeks with a single insert Occludes the punctum Fully biodegradable insert ONGOING PHASE 1 CLINICAL
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
11 Jan 21
Results of Operations and Financial Condition
12:00am
Travoprost loaded microparticles embedded in hydrogel Administered with 27G or 26G needle Resides in the iridocorneal angle Fully biodegradable … biodegradable insert SUSTAINED RELEASE THERAPY FOR DRY EYE DISEASE OTX - CSI INITIATED PHASE 2 TRIAL IN Q3 2020 20
PHASE 1 STUDY OBJECTIVE AND DESIGN 21
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
8 Aug 22
Ocular Therapeutix™ Reports Second Quarter 2022 Financial Results and Business Update
4:09pm
, biodegradable collagen plugs. Specifically, the Company is conducting this trial to explain the magnitude of the placebo effect seen in both the OTX
8-K
EX-99.1
OCUL
Ocular Therapeutix Inc
20 Jan 21
Regulation FD Disclosure
8:04am
a single injection with proprietary injector (26G - 27G) Implant resides in the iridocorneal angle, hydrates in less than 2 minutes Fully biodegradable 6
10-K
0v4tmgvwz3adhv4od
20 Mar 15
Annual report
12:00am
424B4
3r7lhp zabrk7jbi7wo
25 Jul 14
Prospectus supplement with pricing info
12:00am
DRS/A
3rzvr 0alcsykkl
3 Jun 14
Draft registration statement (amended)
12:00am
S-1/A
lkcp0fmdwwmwc visfaa
11 Jul 14
IPO registration (amended)
12:00am